Literature DB >> 27847354

An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity.

Mark Zanin1, Susu Duan2, Sook-San Wong1, Gyanendra Kumar3, Pradyumna Baviskar1, Emily Collin4, Charles Russell1, Subrata Barman1, Benjamin Hause5, Richard Webby6.   

Abstract

Neuraminidase (NA) is a sialidase expressed on the surface of influenza A viruses that releases progeny viruses from the surface of infected cells and prevents viruses becoming trapped in mucus. It is a homotetramer, with each monomer consisting of a transmembrane region, a stalk, and a globular head with sialidase activity. We recently characterized two swine viruses of the pandemic H1N1 lineage, A/swine/Virginia/1814-1/2012 (pH1N1low-1) and A/swine/Virginia/1814-2/2012 (pH1N1low-2), with almost undetectable NA enzymatic activity compared to that of the highly homologous A/swine/Pennsylvania/2436/2012 (pH1N1-1) and A/swine/Minnesota/2499/2012 (pH1N1-2) viruses. pH1N1-1 transmitted to aerosol contact ferrets, but pH1N1low-1 did not. The aim of this study was to identify the molecular determinants associated with low NA activity as potential markers of aerosol transmission. We identified the shared unique substitutions M19V, A232V, D248N, and I436V (N1 numbering) in pH1N1low-1 and pH1N1low-2. pH1N1low-1 also had the unique Y66D substitution in the stalk domain, where 66Y was highly conserved in N1 NAs. Restoration of 66Y was critical for the NA activity of pH1N1low-1 NA, although 19M or 248D in conjunction with 66Y was required to recover the level of activity to that of pH1N1 viruses. Studies of NA stability and molecular modeling revealed that 66Y likely stabilized the NA homotetramer. Therefore, 66Y in the stalk domain of N1 NA was critical for the stability of the NA tetramer and, subsequently, for NA enzymatic activity. IMPORTANCE: Neuraminidase (NA) is a sialidase that is one of the major surface glycoproteins of influenza A viruses and the target for the influenza drugs oseltamivir and zanamivir. NA is important as it releases progeny viruses from the surface of infected cells and prevents viruses becoming trapped in mucus. Mutations in the globular head domain that decrease enzymatic activity but confer resistance to NA inhibitors have been characterized; however, the importance of specific mutations in the stalk domain is unknown. We identified 66Y (N1 numbering), a highly conserved amino acid that was critical for the stability of the NA tetramer and, subsequently, for NA enzymatic activity.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  influenza; neuraminidase; stalk

Mesh:

Substances:

Year:  2017        PMID: 27847354      PMCID: PMC5215329          DOI: 10.1128/JVI.00868-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes.

Authors:  A Krogh; B Larsson; G von Heijne; E L Sonnhammer
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

2.  Roles of neuraminidase in the initial stage of influenza virus infection.

Authors:  Masanobu Ohuchi; Naoko Asaoka; Tatsuya Sakai; Reiko Ohuchi
Journal:  Microbes Infect       Date:  2006-02-08       Impact factor: 2.700

3.  Pandemic Swine H1N1 Influenza Viruses with Almost Undetectable Neuraminidase Activity Are Not Transmitted via Aerosols in Ferrets and Are Inhibited by Human Mucus but Not Swine Mucus.

Authors:  Mark Zanin; Bindumadhav Marathe; Sook-San Wong; Sun-Woo Yoon; Emily Collin; Christine Oshansky; Jeremy Jones; Benjamin Hause; Richard Webby
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

4.  Assembly of subtype 1 influenza neuraminidase is driven by both the transmembrane and head domains.

Authors:  Diogo V da Silva; Johan Nordholm; Ursula Madjo; Annika Pfeiffer; Robert Daniels
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

5.  Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.

Authors:  Mathilde Richard; Olivier Ferraris; Alexandra Erny; Mendy Barthélémy; Aurélien Traversier; Murielle Sabatier; Alan Hay; Yi Pu Lin; Rupert J Russell; Bruno Lina
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

6.  Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.

Authors:  Luis Tolentino-Lopez; Aldo Segura-Cabrera; Paola Reyes-Loyola; Mirko Zimic; Miguel Quiliano; Veronica Briz; Angeles Muñoz-Fernández; Mario Rodríguez-Pérez; Ian Ilizaliturri-Flores; Jose Correa-Basurto
Journal:  Biopolymers       Date:  2013-01       Impact factor: 2.505

7.  Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors.

Authors:  Mathilde Richard; Claire Deléage; Mendy Barthélémy; Yi Pu Lin; Alan Hay; Bruno Lina; Olivier Ferraris
Journal:  J Clin Virol       Date:  2008-01       Impact factor: 3.168

Review 8.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.

Authors:  Olivier Ferraris; Bruno Lina
Journal:  J Clin Virol       Date:  2007-12-11       Impact factor: 3.168

9.  The influenza virus neuraminidase protein transmembrane and head domains have coevolved.

Authors:  Diogo V da Silva; Johan Nordholm; Dan Dou; Hao Wang; Jeremy S Rossman; Robert Daniels
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

10.  Conversion of a class II integral membrane protein into a soluble and efficiently secreted protein: multiple intracellular and extracellular oligomeric and conformational forms.

Authors:  R G Paterson; R A Lamb
Journal:  J Cell Biol       Date:  1990-04       Impact factor: 10.539

View more
  7 in total

1.  Mutation of the Second Sialic Acid-Binding Site, Resulting in Reduced Neuraminidase Activity, Preceded the Emergence of H7N9 Influenza A Virus.

Authors:  Meiling Dai; Ryan McBride; Jos C F M Dortmans; Wenjie Peng; Mark J G Bakkers; Raoul J de Groot; Frank J M van Kuppeveld; James C Paulson; Erik de Vries; Cornelis A M de Haan
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

2.  Swine H1N1 Influenza Virus Variants with Enhanced Polymerase Activity and HA Stability Promote Airborne Transmission in Ferrets.

Authors:  Meng Hu; Jeremy C Jones; Balaji Banoth; Chet Raj Ojha; Jeri Carol Crumpton; Lisa Kercher; Robert G Webster; Richard J Webby; Charles J Russell
Journal:  J Virol       Date:  2022-03-07       Impact factor: 6.549

3.  Structural restrictions for influenza neuraminidase activity promote adaptation and diversification.

Authors:  Hao Wang; Dan Dou; Henrik Östbye; Rebecca Revol; Robert Daniels
Journal:  Nat Microbiol       Date:  2019-08-26       Impact factor: 17.745

Review 4.  From Variation of Influenza Viral Proteins to Vaccine Development.

Authors:  Wandi Zhu; Chao Wang; Bao-Zhong Wang
Journal:  Int J Mol Sci       Date:  2017-07-18       Impact factor: 5.923

5.  Structure-based design of stabilized recombinant influenza neuraminidase tetramers.

Authors:  Daniel Ellis; Julia Lederhofer; Oliver J Acton; Yaroslav Tsybovsky; Sally Kephart; Christina Yap; Rebecca A Gillespie; Adrian Creanga; Audrey Olshefsky; Tyler Stephens; Deleah Pettie; Michael Murphy; Claire Sydeman; Maggie Ahlrichs; Sidney Chan; Andrew J Borst; Young-Jun Park; Kelly K Lee; Barney S Graham; David Veesler; Neil P King; Masaru Kanekiyo
Journal:  Nat Commun       Date:  2022-04-05       Impact factor: 17.694

Review 6.  Inhibition of sialidase activity as a therapeutic approach.

Authors:  Victor Yu Glanz; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  Drug Des Devel Ther       Date:  2018-10-10       Impact factor: 4.162

Review 7.  Influenza A Virus Hemagglutinin-Neuraminidase-Receptor Balance: Preserving Virus Motility.

Authors:  Erik de Vries; Wenjuan Du; Hongbo Guo; Cornelis A M de Haan
Journal:  Trends Microbiol       Date:  2019-10-17       Impact factor: 17.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.